Pharmaceutical Market Europe • January 2021 • 3
COMMENT
2021 definitely did not start the way we had hoped, with the emergence of a new, more transmissible variant of the coronavirus that caused Christmas plans to be severely curtailed and resulted in another countrywide lockdown.
However, in the midst of all the uncertainty, there was a cause for celebration when, on 4 January, a UK patient became the first person in the world to receive AstraZeneca and Oxford University’s COVID-19 vaccine, less than a week after the vaccine was approved by the Medicines and Healthcare products Regulatory Agency.
Along with the race to find a vaccine, there is an equally important search for drugs that can be used to treat those suffering from COVID-19. On page 22, PME talks to Gilead Sciences’ Julian Cole about the company’s efforts to find an effective drug treatment for patients with COVID-19 and the journey of remdesivir that began a decade ago as part of Gilead’s emerging viruses programme.
Also in this month’s issue, we have a focus on the importance of pandemic preparedness. On page 24, Jake Reder talks about why we need to replace our focus of ‘just in time’ with a focus on ‘just in case’ and on page 26, David Veredas talks about the need for an Emergency Health Financing Facility that could be used to limit the impact of future crises on the EU.
While the pandemic rages on, other diseases are getting lost in the chaos, yet the health and treatment of these patients remains equally important. On page 16, PME talks to AstraZeneca’s Joris Silon about the company’s focus on diagnosing and managing chronic kidney disease, which affects approximately 700 million people worldwide.
Despite the fierce ongoing battle against COVID-19, thanks to the continuing efforts of scientists and healthcare professionals around the world, there are still reasons to be hopeful. And on that note, I wish all our readers a Happy New Year!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Reporter
Lucy Parsons
Studio:
Executive Director
Karl Equi
Middleweight Graphic Designer
Helen Penfold
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup
Mansard House, Church Road, Little Bookham, Surrey, KT23 3JG, UK
Tel: +44 (0)1372 414200
Fax: +44 (0)1372 414201
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2021 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW